has been cited by the following article(s):
|
[1]
|
Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trial
|
|
Phytotherapy …,
2022 |
|
|
|
|
[2]
|
Phytochemistry and pharmacology of sea buckthorn (Elaeagnus rhamnoides; syn. Hippophae rhamnoides): progress from 2010 to 2021
|
|
Phytochemistry Reviews,
2022 |
|
|
|
|
[3]
|
Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, United Kingdom 525 B Street, Suite 1650, San Diego, CA 92101, United States …
|
|
2018 |
|
|
|
|
[4]
|
Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway
|
|
RSC Advances,
2017 |
|
|
|
|
[5]
|
Effect of sea buckthorn (Hippophae rhamnoides L.) on blood lipid profiles: a systematic review and meta-analysis from 11 independent randomized controlled trials
|
|
Trends in Food Science & Technology,
2016 |
|
|
|
|
[6]
|
A review of therapeutic and non-therapeutic properties of sea buckthorn
|
|
Advanced Herbal Medicine,
2015 |
|
|
|
|
[1]
|
Phytochemistry and pharmacology of sea buckthorn (Elaeagnus rhamnoides; syn. Hippophae rhamnoides): progress from 2010 to 2021
Phytochemistry Reviews,
2023
DOI:10.1007/s11101-022-09832-1
|
|
|
|
|
[2]
|
Effects of sea buckthorn (Hippophae rhamnoides L.) on factors related to metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trial
Phytotherapy Research,
2022
DOI:10.1002/ptr.7596
|
|
|
|
|
[3]
|
Phytochemistry and pharmacology of sea buckthorn (Elaeagnus rhamnoides; syn. Hippophae rhamnoides): progress from 2010 to 2021
Phytochemistry Reviews,
2022
DOI:10.1007/s11101-022-09832-1
|
|
|
|
|
[4]
|
Management of High Altitude Pathophysiology
2018
DOI:10.1016/B978-0-12-813999-8.00003-3
|
|
|
|
|
[5]
|
Effect of sea buckthorn (Hippophae rhamnoides L.) on blood lipid profiles: A systematic review and meta-analysis from 11 independent randomized controlled trials
Trends in Food Science & Technology,
2017
DOI:10.1016/j.tifs.2016.11.007
|
|
|
|
|
[6]
|
Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway
RSC Adv.,
2017
DOI:10.1039/C7RA03949B
|
|
|
|